Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review.
COPD
bronchiectasis
hazard risk
lung cancer
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
received:
06
12
2022
revised:
23
01
2023
accepted:
31
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Initial evidence supports the hypothesis that patients with non-cystic fibrosis bronchiectasis (NCFB) have a higher risk of lung cancer. We systematically reviewed the available literature to define the characteristics of lung malignancies in patients with bronchiectasis and the characteristics of patients who develop bronchiectasis-associated lung cancer. This study was performed based on the PRISMA guidelines. The review protocol was registered in PROSPERO. The frequency rates of lung cancer in patients with NCFB ranged from 0.93% to 8.0%. The incidence rate was 3.96. Cancer more frequently occurred in the elderly and males. Three studies found an overall higher risk of developing lung cancer in the NCFB population compared to the non-bronchiectasis one, and adenocarcinoma was the most frequently reported histological type. The effect of the co-existence of NCFB and COPD was unclear. NCFB is associated with a higher risk of developing lung cancer than individuals without NCFB. This risk is higher for males, the elderly, and smokers, whereas concomitant COPD's effect is unclear.
Sections du résumé
BACKGROUND
BACKGROUND
Initial evidence supports the hypothesis that patients with non-cystic fibrosis bronchiectasis (NCFB) have a higher risk of lung cancer. We systematically reviewed the available literature to define the characteristics of lung malignancies in patients with bronchiectasis and the characteristics of patients who develop bronchiectasis-associated lung cancer.
METHOD
METHODS
This study was performed based on the PRISMA guidelines. The review protocol was registered in PROSPERO.
RESULTS
RESULTS
The frequency rates of lung cancer in patients with NCFB ranged from 0.93% to 8.0%. The incidence rate was 3.96. Cancer more frequently occurred in the elderly and males. Three studies found an overall higher risk of developing lung cancer in the NCFB population compared to the non-bronchiectasis one, and adenocarcinoma was the most frequently reported histological type. The effect of the co-existence of NCFB and COPD was unclear.
CONCLUSIONS
CONCLUSIONS
NCFB is associated with a higher risk of developing lung cancer than individuals without NCFB. This risk is higher for males, the elderly, and smokers, whereas concomitant COPD's effect is unclear.
Identifiants
pubmed: 36836816
pii: life13020459
doi: 10.3390/life13020459
pmc: PMC9961135
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
BMC Pulm Med. 2016 Nov 15;16(1):151
pubmed: 27846869
Chest. 2017 May;151(5):982-992
pubmed: 27889361
Cancers (Basel). 2022 May 25;14(11):
pubmed: 35681584
Eur Respir J. 2018 Sep 15;52(3):
pubmed: 30049739
BMC Pulm Med. 2019 Feb 28;19(1):54
pubmed: 30819166
Lancet. 2008 Sep 20;372(9643):1107-19
pubmed: 18805339
PLoS One. 2016 Mar 15;11(3):e0150532
pubmed: 26978269
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
JAMA Oncol. 2022 Feb 01;8(2):209-219
pubmed: 34854871
Int J Chron Obstruct Pulmon Dis. 2015 May 04;10:873-9
pubmed: 26005340
Lancet Respir Med. 2016 Dec;4(12):969-979
pubmed: 27864036
Chronic Obstr Pulm Dis. 2022 Jul 29;9(3):454-476
pubmed: 35790131
Am J Respir Crit Care Med. 2022 Apr 15;205(8):894-902
pubmed: 35050830
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Eur Respir J. 2016 Jan;47(1):186-93
pubmed: 26541539
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Thorax. 2010 Sep;65(9):775-81
pubmed: 20805170
Int J Chron Obstruct Pulmon Dis. 2015 Jul 28;10:1465-75
pubmed: 26251586
Thorax. 2004 Aug;59(8):679-81
pubmed: 15282388
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
NPJ Prim Care Respir Med. 2022 Sep 8;32(1):33
pubmed: 36075906
Sci Rep. 2018 Jun 18;8(1):9236
pubmed: 29915333
Respir Med. 2020 Oct;172:106090
pubmed: 32916445
J Thorac Dis. 2018 Jun;10(6):3829-3844
pubmed: 30069384
PLoS One. 2020 Apr 13;15(4):e0231204
pubmed: 32282811
Sci Rep. 2021 Mar 29;11(1):7126
pubmed: 33782457
ERJ Open Res. 2020 Feb 17;6(1):
pubmed: 32083111
Respir Med. 2014 Feb;108(2):287-96
pubmed: 24445062
J Thorac Dis. 2019 Oct;11(Suppl 17):S2155-S2172
pubmed: 31737343
PLoS One. 2018 Aug 16;13(8):e0202360
pubmed: 30114238
Expert Rev Respir Med. 2021 Apr;15(4):477-491
pubmed: 33511899
Chest. 2018 Oct;154(4):737-739
pubmed: 30290922
Thorax. 2020 Jun;75(6):506-509
pubmed: 32241883
Respirology. 2017 Jul;22(5):922-927
pubmed: 28236369
Respir Res. 2017 Dec 19;18(1):211
pubmed: 29258516
Respir Res. 2019 Dec 3;20(1):271
pubmed: 31796019
Int J Mol Sci. 2021 Aug 03;22(15):
pubmed: 34361097
Int J Clin Pract. 2015 Jun;69(6):682-8
pubmed: 25421905
Chest. 2012 Aug;142(2):432-439
pubmed: 22302301
Lancet. 1992 May 23;339(8804):1268-78
pubmed: 1349675
Ann Am Thorac Soc. 2022 Sep;19(9):1551-1560
pubmed: 35533306
Clin Lung Cancer. 2003 Jul;5(1):46-62
pubmed: 14596704
QJM. 2016 Jan;109(1):17-25
pubmed: 25435548
Eur Respir J. 2009 Oct;34(4):843-9
pubmed: 19357155
Int J Mol Sci. 2021 Aug 30;22(17):
pubmed: 34502312